• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab.

作者信息

Avouac Jérôme, Airó Paolo, Carlier Nicolas, Matucci-Cerinic Marco, Allanore Yannick

机构信息

Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France

Department of Rheumatology and Clinical Immunology Service, Spedali Civili di Brescia, Brescia, Italy.

出版信息

Ann Rheum Dis. 2021 Mar;80(3):e37. doi: 10.1136/annrheumdis-2020-217864. Epub 2020 Jun 5.

DOI:10.1136/annrheumdis-2020-217864
PMID:32503849
Abstract
摘要

相似文献

1
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab.3例接受利妥昔单抗治疗的系统性硬化症患者发生的重症新型冠状病毒肺炎相关肺炎。
Ann Rheum Dis. 2021 Mar;80(3):e37. doi: 10.1136/annrheumdis-2020-217864. Epub 2020 Jun 5.
2
Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac .对阿武阿克的《3例接受利妥昔单抗治疗的系统性硬化症患者的重症新型冠状病毒肺炎》的回应
Ann Rheum Dis. 2021 Mar;80(3):e38. doi: 10.1136/annrheumdis-2020-217955. Epub 2020 Jun 5.
3
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.在当代实践中，用利妥昔单抗治疗系统性硬化症患者的结局：一项前瞻性队列研究。
Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9.
4
Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide.利妥昔单抗成功治疗一名对口服类固醇和环磷酰胺耐药的日本系统性硬化症相关间质性肺病患者。
J Dermatol. 2018 Jun;45(6):e140-e141. doi: 10.1111/1346-8138.14189. Epub 2017 Dec 19.
5
Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review.生物药物在儿童局限性硬皮病和系统性硬化症治疗中的应用：一项范围综述。
Semin Arthritis Rheum. 2025 Apr;71:152634. doi: 10.1016/j.semarthrit.2025.152634. Epub 2025 Jan 29.
6
Is biological therapy in systemic sclerosis the answer?生物疗法是系统性硬化症的答案吗？
Rheumatol Int. 2020 May;40(5):679-694. doi: 10.1007/s00296-020-04515-6. Epub 2020 Jan 20.
7
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.利妥昔单抗治疗系统性硬化症难治性指端梗死和溃疡
Clin Rheumatol. 2014 Jul;33(7):1019-20. doi: 10.1007/s10067-014-2579-1. Epub 2014 Apr 12.
8
Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.利妥昔单抗治疗比环磷酰胺治疗更有效用于日本抗拓扑异构酶 I 阳性系统性硬皮病相关间质性肺病患者。
J Dermatol. 2019 Nov;46(11):1006-1013. doi: 10.1111/1346-8138.15079. Epub 2019 Sep 9.
9
Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.系统性硬皮病患者自体造血干细胞移植后的免疫抑制治疗-利妥昔单抗的高疗效。
Front Immunol. 2022 Jan 17;12:817893. doi: 10.3389/fimmu.2021.817893. eCollection 2021.
10
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.一名接受托珠单抗治疗系统性硬化症相关间质性肺病的系统性硬化症患者感染了新冠病毒。
Ann Rheum Dis. 2020 May;79(5):668-669. doi: 10.1136/annrheumdis-2020-217442. Epub 2020 Apr 2.

引用本文的文献

1
COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease.新型冠状病毒肺炎疫苗接种：慢性免疫介导的炎症性疾病患者
Adv Rheumatol. 2023 Nov 1;63(1):54. doi: 10.1186/s42358-023-00335-x.
2
COVID-19 in patients with rheumatological diseases in the Eastern Province of Saudi Arabia.沙特阿拉伯东部省份风湿性疾病患者的 COVID-19 。
J Med Life. 2023 Jun;16(6):873-882. doi: 10.25122/jml-2023-0037.
3
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.
CovAID：炎症性风湿病或自身免疫性疾病患者中与重症COVID-19相关因素的识别
Front Med (Lausanne). 2023 Mar 22;10:1152587. doi: 10.3389/fmed.2023.1152587. eCollection 2023.
4
Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.抗 CD20 单克隆抗体治疗皮肤自身免疫性疾病的综述。
Am J Clin Dermatol. 2023 Mar;24(2):247-273. doi: 10.1007/s40257-022-00751-7. Epub 2023 Jan 11.
5
More difficult still: Treating severe rapidly progressive glomerulonephritis in the context of COVID-19 pneumonia.更困难的是：在 COVID-19 肺炎的背景下治疗严重的快速进行性肾小球肾炎。
Nefrologia (Engl Ed). 2022 Jan-Feb;42(1):94-98. doi: 10.1016/j.nefroe.2020.12.007. Epub 2022 Feb 17.
6
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review.系统性硬化症相关间质性肺病靶向治疗管理方面的开放性问题：基于系统文献综述的EUSTAR调查结果
Ther Adv Musculoskelet Dis. 2022 Aug 22;14:1759720X221116408. doi: 10.1177/1759720X221116408. eCollection 2022.
7
Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis-A case report and literature review.利妥昔单抗治疗的系统性硬化症患者中用于COVID-19肺炎的抗SARS-CoV-2中和单克隆抗体——病例报告及文献综述
Front Med (Lausanne). 2022 Aug 3;9:934169. doi: 10.3389/fmed.2022.934169. eCollection 2022.
8
Systemic sclerosis in the time of COVID-19.新冠疫情时期的系统性硬化症
Lancet Rheumatol. 2022 Aug;4(8):e566-e575. doi: 10.1016/S2665-9913(22)00130-8. Epub 2022 Jul 21.
9
Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.COVID-19疫情期间的天疱疮：感染风险、疫苗反应及管理策略
J Clin Med. 2022 Jul 8;11(14):3968. doi: 10.3390/jcm11143968.
10
Psychological Fragility in an Italian Cohort of Systemic Sclerosis Patients During COVID-19 Pandemic Category: Short Communication.新冠疫情期间意大利系统性硬化症患者队列中的心理脆弱性 类别：简短通讯
Open Access Rheumatol. 2022 Jul 11;14:133-139. doi: 10.2147/OARRR.S367424. eCollection 2022.